Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 5Recruiting 4Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 1

Interventions

Injections 39Carboplatin 33Capecitabine 24Paclitaxel 23Cisplatin 23Docetaxel 22pembrolizumab 21Oxaliplatin 21Gemcitabine 21Bevacizumab 19Pemetrexed 18Fluorouracil 13Irinotecan 12Cyclophosphamide 11osimertinib 9Nivolumab 9Dexamethasone 8Topotecan 7Leucovorin 7130-nm albumin-bound paclitaxel 7venetoclax 6toripalimab 6tislelizumab 6regorafenib 6lenvatinib 6fludarabine 6Doxorubicin 6Cetuximab 6daratumumab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × aumolertinib × Clear all
NCT05503888 2022-08-17

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1/2 Not yet recruiting
160 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡